Prior to joining Principia, Mr. Babler was President and Chief Executive Officer of Talima Therapeutics, Inc. Previously he held positions of increasing responsibility at Genentech, Inc., most recently as Vice President, Immunology Sales and Marketing. He began his pharmaceutical industry career at Eli Lilly and Company focused on sales, sales management, global marketing and business development. Mr. Babler also is a Member of the Board of Directors of INFINITY Pharmaceuticals and a Guest Lecturer for the BioExec Institute at the Haas School of Business at the University of California, Berkeley. He also serves on the BIO Board of Directors. He holds a Swiss Federal Diploma in Pharmacy from the Federal Institute of Technology in Zurich. Mr. Babler also graduated from the Executive Development Program at the Kellogg Graduate School of Management at Northwestern University.
Prior to joining Principia, Mr. Chai served as Senior Vice President and Chief Financial Officer at MAP Pharmaceuticals, Inc., where he played an integral role in its growth, including an IPO and its eventual sale in 2013 to Allergan, Inc. From 1998 to 2006, Mr. Chai was employed by CV Therapeutics, Inc., a biopharmaceutical company, where he held various management positions, including Vice President, Treasury and Investor Relations. Mr. Chai also worked at J.P. Morgan & Co. Incorporated in various capacities, including as a healthcare investment banker. Mr. Chai received a B.S. in operations research and industrial engineering from Cornell University.
Prior to joining Principia, Dr. Gourlay was a partner at GBS Venture Partners, a specialist life sciences investment firm, where he served as both investment manager and consultant clinical development advisor across the portfolio. Previously he held positions of increasing responsibility at Genentech, Inc., most recently as Senior Director, Clinical & Experimental Pharmacology and Toxicology. Dr. Gourlay holds a medical degree from the University of Melbourne, a PhD in Medicine from Monash University and a MBA from Macquarie University.
Prior to joining Principia, Dr. Funk served as Senior Vice President of R&D and Global Head of the Therapeutic Area Oncology at Merck Serono, Merck KGaA. While at Merck Serono he led the advancement of its oncology portfolio, focusing on small molecule and biologics discovery. Before joining Merck KGaA, Dr. Funk focused on cancer and immune/inflammatory diseases in research and clinical positions at UCSF, the Fred Hutchinson Cancer Research Center, and the Universities of Erlangen and Munich. Dr. Funk received his medical and scientific training at Stanford University, the University of Edinburgh and the University of Lübeck, where he graduated with an M.D. Dr. Funk has brought more than ten novel drug candidates into clinical development and has co-authored numerous scientific articles in international peer-reviewed journals. Dr. Funk is board certified in dermatology.
Prior to joining Principia, Ms. Adams was a business development consultant for both private and public companies in the biotechnology field, including Affymax, Proteolix, and Aerovance. Before launching her consulting practice, Ms. Adams spent several years at Aviron, most recently as Director, Corporate Development. She has also worked in business development at Genentech. Earlier, Ms. Adams worked for Cowen & Company providing corporate finance and strategic advisory services for clients in the biotech, medical device, and healthcare services sectors. Ms. Adams also serves on the Advisory Board of the Bay Area Lyme Foundation, and on the Emeritus Board of the Boys and Girls Club of the Peninsula. She received an A.B. degree in Comparative Area Studies from Duke University and an M.B.A. from the. Haas School of Business at U.C. Berkeley.
Prior to joining Principia Dr. Goldstein held positions of increasing responsibility at Roche, most recently serving as Senior Director, Medicinal Chemistry and Head of Inflammation Chemistry. Dr. Goldstein also was previously a Consulting Assistant Professor at Stanford University. He received a B.A. in Chemistry from Franklin and Marshall College and a Ph.D. in Chemistry from the University of Virginia.
Prior to joining Principia, Mr. van Houte served as a contract CFO for several life science companies. Previous experience includes positions of Vice President, Finance and Administration for Allozyne, Inc., Vice President, Finance and Administration for Trubion Pharmaceuticals, and Vice President of Finance for Ostex International. He began his career as the Controller, Assistant Treasurer and Principal Accounting Officer for Vertex Pharmaceuticals, Inc. Mr. van Houte received his B.S. in Finance and Management from Babson College.
Prior to joining Principia, Dr. Brameld most recently held the positions of Computational Chemistry Group Leader and Principal Research Scientist at Roche. His previous experience also includes senior scientific positions at leading biopharmaceutical companies, including Celera Genomics, Array Biopharma, and Scios, Inc. Dr. Brameld received a B.S. in Chemistry from the University of Washington and a Ph.D. in Chemistry from the California Institute of Technology.